A detailed history of Ahrens Investment Partners LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Ahrens Investment Partners LLC holds 11,000 shares of EXEL stock, worth $385,549. This represents 0.11% of its overall portfolio holdings.

Number of Shares
11,000
Previous 11,000 -0.0%
Holding current value
$385,549
Previous $176,000 21.02%
% of portfolio
0.11%
Previous 0.08%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 21, 2022

BUY
$15.84 - $21.88 $1,584 - $2,188
100 Added 0.92%
11,000 $201,000
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $165,135 - $205,901
10,900 New
10,900 $192,000
Q3 2017

Oct 19, 2017

SELL
$23.35 - $29.24 $840,600 - $1.05 Million
-36,000 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
200 Added 0.56%
36,000 $887,000
Q1 2017

Aug 22, 2017

BUY
N/A
6,900 Added 23.88%
35,800 $776,000
Q4 2016

Aug 23, 2017

BUY
N/A
28,900
28,900 $431,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Ahrens Investment Partners LLC Portfolio

Follow Ahrens Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ahrens Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ahrens Investment Partners LLC with notifications on news.